{
  "docId": "019de070-6ba7-74d1-848b-b84c997820ae",
  "docSlug": "fd4b4c87c265fc439333e9f58c5ae8a7",
  "documentTitle": "Compass Therapeutics | IPO Presentation Deck | 40 slides",
  "authorId": "compass-therapeutics",
  "authorName": "Compass Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2020-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 24,
  "pageCount": 40,
  "prevPage": 23,
  "nextPage": 25,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 8,
  "notes": "Clinical trial update slide.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-6ba7-74d1-848b-b84c997820ae/24",
  "deckHref": "/decks/019de070-6ba7-74d1-848b-b84c997820ae",
  "deckJsonHref": "/decks/019de070-6ba7-74d1-848b-b84c997820ae.json",
  "deckAnchorHref": "/decks/019de070-6ba7-74d1-848b-b84c997820ae#slide-24",
  "components": [
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.35,
        "y": 0.95
      },
      "kind": "disclaimer",
      "text": "DO NOT DISTRIBUTE WITHOUT PERMISSION | © 2020",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fbd2dfe9-8236-4806-b2a9-1ad20f8bda5c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.85,
        "x": 0.05,
        "y": 0.42
      },
      "kind": "list",
      "text": "Preliminary signals of antitumor activity and biological activity; Two patients with NSCLC stable disease; One patient with metastatic melanoma with 24% decline in target lesions; Clear cytokine changes",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "11de3037-a48d-4c44-8b6b-4659ee9bda9c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.8,
        "x": 0.05,
        "y": 0.68
      },
      "kind": "list",
      "text": "Part 2 initiated: first patient dosed; 60 patients to be enrolled in Phase 1b; H1 2021 data read; Planning for Herceptin and/or Erbitux combination study",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3482f32d-50d1-416f-9353-b4296abdf1d6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.8,
        "x": 0.05,
        "y": 0.15
      },
      "kind": "list",
      "text": "Dose Escalation Part 1 completed; 19 patients enrolled; CTX-471 well tolerated; MTD 0.6 mg/kg (~70% receptor occupancy); Dose limiting toxicity: thrombocytopenia",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "62b8c6f3-d614-4109-9696-08da49454819",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.45,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "CTX-471 Phase 1 Summary",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "01bbbdf4-0b88-4ca4-ace8-17422d611f19",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "2e4a97cd-9db6-4a4f-bdb2-a3aa5ab004f4",
      "evidence": "list/bullet: Preliminary signals of antitumor activity and biological activity; Two patients with NSCLC stable disease; One patient with metastatic melanoma with 24% decline in target lesions; Clear cytokine changes",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 24,
      "from": 7,
      "beatId": "4189f97c-14ae-46e9-86c5-8cb495a87bea",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "Slides 7-24: Overview of Compass Proprietary Technologies, Pipeline, and clinical data",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 40,
      "from": 4,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "8f23aa4f-73de-402c-b124-1353a7937adb",
      "evidence": "The deck presents a clear 'why' throughout, with a focus on the team's expertise and the pipeline's potential",
      "position": 1,
      "objective": "Why Compass Therapeutics, and why now?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}